Susan Greenbloom

1.9k total citations
24 papers, 427 citations indexed

About

Susan Greenbloom is a scholar working on Epidemiology, Hepatology and Genetics. According to data from OpenAlex, Susan Greenbloom has authored 24 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 14 papers in Hepatology and 9 papers in Genetics. Recurrent topics in Susan Greenbloom's work include Hepatitis C virus research (12 papers), Liver Disease Diagnosis and Treatment (9 papers) and Inflammatory Bowel Disease (8 papers). Susan Greenbloom is often cited by papers focused on Hepatitis C virus research (12 papers), Liver Disease Diagnosis and Treatment (9 papers) and Inflammatory Bowel Disease (8 papers). Susan Greenbloom collaborates with scholars based in Canada, United States and Spain. Susan Greenbloom's co-authors include A. Hillary Steinhart, Gordon R. Greenberg, Thomas Sylwestrowicz, Gerald W. Dryden, Bruce E. Sands, Ziad Younes, Richard N. Fedorak, Eric Jacobson, Tuan Nguyen and Lennox J. Jeffers and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Susan Greenbloom

24 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan Greenbloom Canada 10 262 184 138 70 67 24 427
Michiaki Okada Japan 11 202 0.8× 73 0.4× 123 0.9× 144 2.1× 273 4.1× 22 618
Yukio Itoh Japan 10 268 1.0× 53 0.3× 246 1.8× 23 0.3× 148 2.2× 20 509
Julia Hengst Germany 14 398 1.5× 59 0.3× 381 2.8× 581 8.3× 58 0.9× 19 968
P Leinikki Finland 10 123 0.5× 182 1.0× 19 0.1× 89 1.3× 110 1.6× 26 407
John Bial United States 9 116 0.4× 33 0.2× 115 0.8× 79 1.1× 39 0.6× 11 603
Jose A. Garcia-Rivera United States 11 161 0.6× 32 0.2× 185 1.3× 32 0.5× 139 2.1× 18 426
Elaine A. Hopes United Kingdom 8 219 0.8× 43 0.2× 119 0.9× 86 1.2× 35 0.5× 8 363
Seyed Mohammad Jazayeri Iran 15 531 2.0× 18 0.1× 445 3.2× 70 1.0× 91 1.4× 80 724
Winnie H. Sim Australia 8 142 0.5× 112 0.6× 11 0.1× 33 0.5× 110 1.6× 8 383

Countries citing papers authored by Susan Greenbloom

Since Specialization
Citations

This map shows the geographic impact of Susan Greenbloom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Greenbloom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Greenbloom more than expected).

Fields of papers citing papers by Susan Greenbloom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Greenbloom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Greenbloom. The network helps show where Susan Greenbloom may publish in the future.

Co-authorship network of co-authors of Susan Greenbloom

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Greenbloom. A scholar is included among the top collaborators of Susan Greenbloom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Greenbloom. Susan Greenbloom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loftus, Edward V., Jean‐Frédéric Colombel, Ana P. Lacerda, et al.. (2022). S736 Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From a Randomized Phase 3 U-EXCEL Study. The American Journal of Gastroenterology. 117(10S). e518–e518. 2 indexed citations
2.
Colombel, Jean–Frédéric, Julián Panés, Ana P. Lacerda, et al.. (2022). 867f: EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO FAILED PRIOR BIOLOGICS: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEED STUDY. Gastroenterology. 162(7). S–1394. 8 indexed citations
3.
Vermeire, Séverine, Silvio Danese, Wen Zhou, et al.. (2021). S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study. The American Journal of Gastroenterology. 116(1). S357–S357. 1 indexed citations
4.
Sandborn, William J., Julián Panés, Laurent Peyrin‐Biroulet, et al.. (2020). DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study. Journal of Crohn s and Colitis. 14(Supplement_1). S117–S118. 3 indexed citations
5.
Gane, Edward, Fred Poordad, Neddie Zadeikis, et al.. (2019). Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease. Clinical Infectious Diseases. 69(10). 1657–1664. 23 indexed citations
6.
7.
Locarnini, SA, K. Jackson, Renae Walsh, et al.. (2018). Inarigivir: a novel RIG-I agonist for chronic hepatitis B. 1 indexed citations
8.
Gane, Edward, Fred Poordad, Joaquin Valdes, et al.. (2017). Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology. 152(5). S1089–S1089. 1 indexed citations
9.
Gane, E., F. Poordad, Joaquin Valdes, et al.. (2017). Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Journal of Hepatology. 66(1). S306–S306. 3 indexed citations
10.
Greenbloom, Susan, et al.. (2017). SB 9200 an oral selective immunomodulator is safe and efficacious in treatment-naive, non-cirrhotic HBV patients: Results from Cohort 1 of the ACHIEVE trial. 4 indexed citations
11.
Gane, Edward, Jacob Lalezari, Armen Asatryan, et al.. (2016). 755 100% Svr4 and Favorable Safety of Abt-493 + Abt-530 Administered for 12 Weeks in Non-Cirrhotic Patients With Genotypes 4, 5, or 6 Infection (Surveyor-I). Gastroenterology. 150(4). S1047–S1047. 2 indexed citations
12.
13.
Zoulim, Fabien, Giampiero Carosi, Susan Greenbloom, et al.. (2014). Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. Journal of Hepatology. 62(1). 56–63. 55 indexed citations
14.
Cooper, Curtis, Stephen D. Shafran, Susan Greenbloom, et al.. (2014). Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy. Canadian Journal of Gastroenterology and Hepatology. 28(1). 35–40. 6 indexed citations
15.
Sherman, Morris, Alnoor Ramji, Susan Greenbloom, et al.. (2011). Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa‐2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. Alimentary Pharmacology & Therapeutics. 35(1). 37–47. 9 indexed citations
16.
Sands, Bruce E., Eric Jacobson, Thomas Sylwestrowicz, et al.. (2009). Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflammatory Bowel Diseases. 16(7). 1209–1218. 78 indexed citations
17.
Pappas, S. Chris, Lisa M. Nyberg, Susan Greenbloom, et al.. (2006). 734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial. Journal of Hepatology. 44. S271–S271. 23 indexed citations
18.
Greenbloom, Susan, A. Hillary Steinhart, & Gordon R. Greenberg. (1998). Combination Ciprofloxacin and Metronidazole for Active Crohn’s Disease. SHILAP Revista de lepidopterología. 12(1). 53–56. 134 indexed citations
19.
Greenbloom, Susan, et al.. (1997). Outbreak of Trichinosis in Ontario Secondary to the Ingestion of Wild Boar Meat. Canadian Journal of Public Health. 88(1). 52–56. 21 indexed citations
20.
Greenbloom, Susan, et al.. (1995). Total enteral immunomodulatory nutrition (TEIN) treatment for severe active ulcerative colitis. Gastroenterology. 108(4). A827–A827. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michiaki Okada Breakdown of academic impact, for papers by Yukio Itoh Breakdown of academic impact, for papers by Julia Hengst Breakdown of academic impact, for papers by P Leinikki Breakdown of academic impact, for papers by John Bial Breakdown of academic impact, for papers by Jose A. Garcia-Rivera Breakdown of academic impact, for papers by Elaine A. Hopes Breakdown of academic impact, for papers by Seyed Mohammad Jazayeri Breakdown of academic impact, for papers by Winnie H. Sim
Rankless by CCL
2026